Veterans Seek Alternatives in Mexico Amid Texas Struggles

As some veterans head to Mexico searching for psychedelic treatments, frustrations are growing in Texas over legal access to similar substances.

One such substance is ibogaine, a psychedelic derived from the iboga shrub found in Africa. A group of military veterans advocates for its use, believing it offers significant benefits for those suffering from PTSD and traumatic brain injuries.

In recent years, veterans have traveled south to try treatments that are not available in the U.S., returning with powerful stories of recovery. Meanwhile, the drug remains inaccessible in the country, and research into its effects is quite challenging. Texas has made attempts to address this with proposed legislation.

“Medical use is clear,” one advocate noted. “We’ve sent over a thousand veterans to Mexico, and we see how it changes their lives.”

There’s a heightened conversation around clinical research into Schedule I substances, classified as illegal due to their potential for abuse and lack of medical acceptance. Former Texas Governor Rick Perry argues ibogaine’s classification is outdated and that it could save many veterans grappling with unseen injuries.

Reflecting on the situation, Perry remarked, “If you’d told me six years ago that I’d be discussing psychedelics, I would have laughed.”

Supporters, like those who have personally experienced improvements from ibogaine, resonate with this perspective. They include veterans who struggle with various forms of mental and physical trauma, sharing their stories in ongoing discussions about treatment options.

Retired Navy SEAL Marcus Capone, who has served multiple tours, and his wife Amber have taken their advocacy to lawmakers in Texas, pushing for research into psychedelic therapies. Amber’s motivation stems from personal loss; after losing a close friend to suicide, she felt compelled to advocate for change.

They argue that existing classifications ignore the growing body of evidence that supports ibogaine’s therapeutic potential. However, changing these classifications presents its own difficulties.

“The challenge lies in the status of Schedule I drugs,” noted Dr. Nolan Williams, a Stanford researcher. He highlighted that despite being documented as beneficial for over a century, many barriers impede progress.

This year, Texas Governor Greg Abbott expanded ibogaine research possibilities with a new bill. Abbott emphasized the pressing need for alternatives, noting, “Texas has the highest veteran population, many of whom are dealing with both visible and invisible wounds.” He expressed hope that ibogaine could offer solutions, particularly for opioid addiction and other mental health issues.

Those supporting the push for ibogaine research hope to amplify voices and stories from individuals who’ve struggled and found potential relief through psychedelic treatments.